ASX:LSH

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. More Details


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Lifespot Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: LSH's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.7%

LSH

10.8%

AU Healthcare Services

0.5%

AU Market


1 Year Return

23.1%

LSH

-8.6%

AU Healthcare Services

-5.6%

AU Market

Return vs Industry: LSH exceeded the Australian Healthcare Services industry which returned -8.6% over the past year.

Return vs Market: LSH exceeded the Australian Market which returned -5.6% over the past year.


Shareholder returns

LSHIndustryMarket
7 Day6.7%10.8%0.5%
30 Day42.2%19.4%5.0%
90 Day60.0%16.4%2.9%
1 Year23.1%23.1%-8.2%-8.6%-2.3%-5.6%
3 Year-46.7%-46.7%220.6%217.3%12.4%-1.2%
5 Yearn/a220.1%210.4%41.5%12.9%

Price Volatility Vs. Market

How volatile is Lifespot Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Lifespot Health undervalued compared to its fair value and its price relative to the market?

12.87x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate LSH's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: LSH is unprofitable, so we can't compare its PE Ratio to the XX Healthcare Services industry average.

PE vs Market: LSH is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate LSH's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: LSH is overvalued based on its PB Ratio (12.9x) compared to the AU Healthcare Services industry average (5.8x).


Next Steps

Future Growth

How is Lifespot Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

33.0%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Lifespot Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Lifespot Health performed over the past 5 years?

-7.1%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: LSH is currently unprofitable.

Growing Profit Margin: LSH is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: LSH is unprofitable, and losses have increased over the past 5 years at a rate of 7.1% per year.

Accelerating Growth: Unable to compare LSH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: LSH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (-4.5%).


Return on Equity

High ROE: LSH has a negative Return on Equity (-376.34%), as it is currently unprofitable.


Next Steps

Financial Health

How is Lifespot Health's financial position?


Financial Position Analysis

Short Term Liabilities: LSH's short term assets (A$656.6K) exceed its short term liabilities (A$232.6K).

Long Term Liabilities: LSH has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: LSH is debt free.

Reducing Debt: LSH has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: LSH has sufficient cash runway for 4 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: LSH is forecast to have sufficient cash runway for 4 months based on free cash flow estimates, but has since raised additional capital.


Next Steps

Dividend

What is Lifespot Health current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate LSH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate LSH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if LSH's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if LSH's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of LSH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.5yrs

Average board tenure


CEO

Matthew Golden

no data

Tenure

Mr. Matthew Golden serves as Chief Executive Officer at Lifespot Health Ltd since October 12, 2020. Mr. Golden is a commercial healthcare Professional with experience in the pharmaceutical industry both in ...


Board Members

NamePositionTenureCompensationOwnership
Justyn Stedwell
Company Secretary & Non-Executive Director0.42yrAU$1.00kno data
Francesco Cannavo
Non-Executive Director4.5yrsAU$58.06kno data
Rodney Andrew Hannington
Non-Executive Chairman2.5yrsAU$152.26k0.39%
A$ 30.2k

2.5yrs

Average Tenure

Experienced Board: LSH's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: LSH insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 56.9%.


Top Shareholders

Company Information

Lifespot Health Ltd's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Lifespot Health Ltd
  • Ticker: LSH
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Technology
  • Sector: Healthcare
  • Market Cap: AU$7.787m
  • Shares outstanding: 121.67m
  • Website: https://www.lifespot-health.com

Location

  • Lifespot Health Ltd
  • 2 Queen Street
  • Suite 103
  • Melbourne
  • Victoria
  • 3000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
LSHASX (Australian Securities Exchange)YesCommon stockAUAUDJan 2017
LSHCHIA (Chi-X Australia)YesCommon stockAUAUDJan 2017
L2HDB (Deutsche Boerse AG)YesCommon stockDEEURJan 2017

Biography

Lifespot Health Ltd, together with its subsidiaries, focuses on the development and commercialization of medical diagnostic and monitoring technology solutions in Australia and Germany. The company is deve ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/20 10:46
End of Day Share Price2020/10/20 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.